Monday, August 14, 2017

Critical Outcome Technologies - COT.v

Critical Outcome Technologies - COT.v represents a multi-pronged approach to value creation in the biopharmaceutical space.

In addition to a potential breakthrough treatment for many cancers, COTI has a robust pipeline of compounds, R&D collaborations and other applications of its core technology.

On August 14, 2017 the company released News

Critical Outcome Technologies Inc. has completed the dose escalation portion of its phase 1 study of COTI-2 in women with advanced gynecologic cancers who have failed conventional therapy. In addition, COTI announced that it has initiated an expansion arm of its Phase 1 study in patients with head and neck squamous cell carcinoma (HNSCC). The Dose Escalation Committee (DEC), comprised of clinical site investigators, an independent medical monitor and Company representatives, met on Friday, August 11, 2017. The initial clinical data were reviewed and the DEC unanimously voted to complete this phase of the trial and progress the study